微生物群失调与B细胞非霍奇金淋巴瘤侵袭性组织学及不良临床结局相关
本研究在Mayo Clinic和NYU Langone Health招募DLBCL、MZL和FL患者,用16S rRNA基因测序分析治疗前肠道微生物群(GMB)。发现淋巴瘤患者GMB组成与健康对照显著不同(P<.001),DLBCL与惰性淋巴瘤GMB组成显著不同(P=.01),且治疗前GMB多样性和组成显著预测免疫化疗反应(P=.01)。
要点
- 淋巴瘤患者治疗前肠道微生物群组成与健康对照显著不同(P<.001)。
- DLBCL患者GMB组成与惰性淋巴瘤显著不同(P=.01),多样性降低呈趋势(P=.08)。
- 治疗前GMB多样性和组成显著预测免疫化疗反应(P=.01)。
核心结论
- 治疗前肠道微生物群失调与B细胞非霍奇金淋巴瘤侵袭性组织学及不良临床结局相关。
研究设计与样本
- 在Mayo Clinic(明尼苏达)和Perlmutter Cancer Center(NYU Langone Health)招募DLBCL、MZL和FL患者。
- 采用16S ribosomal RNA基因测序分析治疗前肠道微生物群(GMB)。
- 比较淋巴瘤患者(51例)与健康对照(58例)、侵袭性DLBCL(8例)与惰性FL/MZL(18例)、以及GMB与免疫化疗结局(8例应答者,6例无应答者)。
主要发现
- 淋巴瘤患者治疗前GMB组成与健康对照显著不同(P < .001)。
- DLBCL患者GMB组成与惰性患者显著不同(P = .01),DLBCL患者微生物多样性降低呈趋势(P = .08)。
- 治疗前GMB多样性和组成显著预测治疗反应(P = .01)。
临床怎么用
- 若结果被验证,可通过改进药物管理及测试GMB靶向疗法来改善患者结局。
局限性
- 样本量小,结果应视为初步原理验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated the association of GMB composition and diversity with lymphoma biology and treatment outcome. Patients with diffuse large B-cell lymphoma (DLBCL), marginal zone (MZL), and follicular lymphoma (FL) were recruited at Mayo Clinic, Minnesota, and Perlmutter Cancer Center, NYU Langone Health. The pretreatment GMB was analyzed using 16S ribosomal RNA gene sequencing. We examined GMB compositions in 3 contexts: lymphoma patients (51) compared with healthy controls (58), aggressive (DLBCL) (8) compared with indolent (FL, MZL) (18), and the association of GMB with immunochemotherapy treatment outcomes (8 responders, 6 nonresponders). Respectively, we found that the pretreatment GMB in lymphoma patients had a distinct composition compared with healthy controls (P < .001); GMB compositions in DLBCL patients were significantly different than indolent patients (P = .01) with a trend toward reduced microbial diversity in DLBCL patients (P = .08); and pretreatment GMB diversity and composition were significant predictors of treatment responses (P = .01). The impact of these pilot results is limited by our small sample size, and should be considered a proof of principle. If validated, our results could lead toward improved treatment outcomes by improving medication stewardship and informing which GMB-targeted therapies should be tested to improve patient outcomes.
引用
- Diefenbach CS, Peters BA, Li H, et al. Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. Blood Adv. 2021. PMID: 33635332. doi:10.1182/bloodadvances.2020003129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。